Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome

• US 20030232400A1
• Filed: 05/15/2003
• Published: 12/18/2003
• Est. Priority Date: 12/20/2002
• Status: Abandoned Application

• Current Assignee: Pamela Pavco, Roger Aitchison, Susan Radka
• Original Assignee: Pamela Pavco, Roger Aitchison, Susan Radka
• Inventors: Aitchison, Roger, Pavco, Pamela, Radka, Susan
• Application Number:
  US10/438,493
• Publication Number:
  US 20030232400A1
• Time in Patent Office: Days
• US Class Current: 435/7.23
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/71 for growth factors; for growth regulators
• CPC Class Codes: G01N 2333/71 for growth factors; for growth regulators
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/57488 involving compounds identifable in body fluids

Abstract

This invention relates generally to compounds and methods relating to detection of soluble VEGFR expression for generating prognostic criteria useful in establishing methods of treatment in cancer patients. In the method of the present invention, soluble VEGFR levels are utilized as a means by which cancer can be detected, efficacy of cancer therapies can be evaluated, prognosis of a subject can be predicted, and new anti-cancer therapies can be discovered.

Claims

1. A method comprising:

(a) assaying a level of soluble VEGFR in a sample; and

(b) correlating said level with a level of membrane bound VEGFR in a subject from which said sample is derived.

2. The method of claim 1, wherein said sample is selected from the group consisting of blood, serum, urine, and tissue sample.

3. The method of claim 1, wherein said subject is a cancer subject.

4. The method of claim 3, wherein said cancer is colorectal cancer, breast cancer, or non-small cell lung cancer (NSLC).

5. The method of claim 1, wherein said assay comprises enzyme-linked immunosorbant assay (ELISA).

6. The method of claim 1, wherein said correlating comprises use of a standard curve of soluble VEGFR levels compared to membrane bound VEGFR levels.

7. A method for identifying cancer in a subject having elevated levels of membrane bound VEGFR, comprising:

(a) assaying a level of soluble VEGFR in a sample from the subject,

(b) determining a level of membrane bound VEGFR in said subject, and

(c) determining whether said subject has cancer based upon the level of soluble or membrane bound VEGFR in the subject.

8. The method of claim 7, wherein said sample is selected from the group consisting of blood, serum, urine, and tissue sample.

9. The method of claim 7, wherein said cancer is colorectal cancer, breast cancer, or non-small cell lung cancer (NSLC).

10. The method of claim 7, wherein said determining whether said subject has cancer based on the level of soluble or membrane bound VEGFR in the subject comprises use of a standard curve of soluble or membrane bound VEGFR levels compared to observed cancer phenotypes associated with soluble or membrane bound VEGFR levels.

11. A method for determining efficacy of a cancer treatment in a subject, comprising:

(a) assaying a level of soluble VEGFR in a sample from said subject prior to said cancer treatment,

(b) assaying a level of soluble VEGFR in a sample from said subject during or after said cancer treatment; and

(c) determining efficacy of said treatment by comparing the level of soluble VEGFR in a sample from said subject prior to said cancer treatment to the level of soluble VEGFR in a sample from said subject during or after said cancer treatment.

12. The method of claim 11, wherein said cancer treatment comprises treatment with a siNA molecule.

13. The method of claim 11, wherein said sample is selected from the group consisting of blood, serum, urine, and tissue.

14. The method of claim 11, wherein said cancer is colorectal cancer, breast cancer, or non-small cell lung cancer (NSLC).

15. The method of claim 11, wherein a level of soluble VEGFR that is lower in (b) compared to (a) indicates efficacy for a cancer treatment.

16. A method for predicting prognostic outcome of a cancer subject, comprising:

(a) assaying a level of soluble VEGFR in a sample from said subject, and

(b) using the level of soluble VEGFR in the subject under conditions suitable to predict prognostic outcome of said subject.

17. A method for predicting prognostic outcome of a subject undergoing cancer treatment, comprising:

(a) assaying a level of soluble VEGFR in a sample from said subject prior to said cancer treatment,

(b) assaying a level of soluble VEGFR in a sample from said subject during or after cancer treatment, and

(c) predicting prognostic outcome of said subject undergoing said cancer treatment by comparing the level of soluble VEGFR in a sample from said subject prior to said cancer treatment to the level of soluble VEGFR in a sample from said subject during or after cancer treatment.

18. The method of claim 17, wherein said cancer treatment comprises treatment With a siNA molecule.

19. The method of claim 17, wherein said sample is selected from the group consisting of blood, serum, urine, and tissue sample.

20. The method of claim 17, wherein said cancer is colorectal cancer, breast cancer, or non-small cell lung cancer (NSLC).

21. The method of claim 17, wherein a level of soluble VEGFR that is lower in (b) compared to (a) indicates efficacy for a treatment.